Effect of bevacizumab combined with carboplatin and docetaxel on serum-related factors and prognosis in recurrent ovarian cancer
Objective To investigate the effect of bevacizumab combined with carboplatin and docetaxel on the serum related factors and prognosis of recurrent ovarian cancer.Methods A total of 32 patients with recurrent ovarian cancer admitted from 2022.1.1 to 2023.6.30 were selected as the study subjects,and they were divided into the study group(n=16)and the control group(n=16)by simple random grouping method.The control group was treated with carboplatin and docetaxel,and the study group was treated with a combination of bevacizumab,carboplatin and docetaxel.The tumor markers[carbohydrate antigen 125(CA125),human epididymal protein 4(HE4)]and vascular endothelial growth factor(VEGF)before and after 6 courses of treatment were compared between the two groups,and the adverse reactions and short-term efficacy of the two groups were compared.Results After treatment,the CA125 and HE4 levels in the two groups decreased compared with those before treatment(P＜0.05).After treatment,the CA125 and HE4 levels in the study group were lower than those in the control group(P＜0.05).After treatment,the VEGF in the two groups decreased compared with that before treatment(P＜0.05),and after treatment,the VEGF in the study group was lower than that in the control group(P＜0.05).The total incidence of adverse reactions in the study group was 62.50%compared with that in the control group(50.00%)after 6 courses of treatment,and the difference was not statistically significant(P＞0.05).After 6 courses of treatment,the RR and DCR of the study group were significantly higher than those of the control group(P＜0.05).Conclusion Bevacizumab combined with carbo-platin and docetaxel in the treatment of recurrent ovarian cancer can improve the levels of tumor markers and vascular growth factor,and improve the anti-tumor effect,with significant efficacy and high safety.
NETL
NSTL
万方数据
